Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: beta-glucan Clear all
Completed Phase 1Phase 2 Interventional

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

NCT00911560
View directory record Official record
Conditions
Neuroblastoma
Interventions
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH, oral β-glucan
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 20, 2026, 11:57 AM EDT
Terminated Not applicable Interventional

MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

NCT03461354
View directory record Official record
Conditions
Mucositis Oral, Head and Neck Cancer
Interventions
MucoLox, Sodium Bicarbonate
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 2 Interventional

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

NCT00089258
View directory record Official record
Conditions
Neuroblastoma
Interventions
beta-glucan, monoclonal antibody 3F8, sargramostim, isotretinoin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 20, 2026, 11:57 AM EDT
Terminated Phase 1 Interventional

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

NCT00087009
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder
Interventions
beta-glucan, rituximab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma

NCT00037011
View directory record Official record
Conditions
Neuroblastoma
Interventions
beta-glucan, monoclonal antibody 3F8
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 49 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

NCT00492167
View directory record Official record
Conditions
Neuroblastoma
Interventions
beta-glucan, monoclonal antibody 3F8, immunohistochemistry staining method, laboratory biomarker analysis
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
0 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 20, 2026, 11:57 AM EDT
Not listed Phase 2 Interventional

A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease

NCT05607615
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Hydroxypropyl Beta Cyclodextrin, Placebo
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Brooksville, Florida • Winter Park, Florida • Marrero, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 20, 2026, 11:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Diagnosis of Candidiasis in Premature Infants

NCT00109525
View directory record Official record
Conditions
Infection, Candida, Candidiasis, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
3 Days to 120 Days
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

NCT00877110
View directory record Official record
Conditions
Neuroblastoma, Bone Marrow, Sympathetic Nervous System
Interventions
cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease

NCT01747135
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
VTS-270
Drug
Lead sponsor
Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company
Industry
Eligibility
2 Years to 25 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

NCT02939547
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-beta-cyclodextrin
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Oakland, California • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 3 Interventional Results available

Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis

NCT00904995
View directory record Official record
Conditions
Leukemia, Fungal Infection
Interventions
Voriconazole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 20, 2026, 11:57 AM EDT
Terminated Phase 1Phase 2 Interventional

Beta-glucan and Fatigue in HSCT Survivors

NCT05524688
View directory record Official record
Conditions
Autologous Haemopoietic Stem Cell Transplant
Interventions
Beta-glucan, Placebo
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 20, 2026, 11:57 AM EDT
Terminated Phase 3 Interventional Results available

Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System

NCT03643562
View directory record Official record
Conditions
Niemann-Pick Type C Disease
Interventions
Adrabetadex
Drug
Lead sponsor
Mandos LLC
Industry
Eligibility
4 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Tolerability of Oat Fiber (BG-OS) in Healthy Individuals

NCT06739941
View directory record Official record
Conditions
Digestive Health, Metabolic Health
Interventions
Oat fiber (BG-OS)
Other
Lead sponsor
One Bio Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 20, 2026, 11:57 AM EDT
Terminated Phase 4 Interventional Results available

Preadmission Skin Wipe Use for Surgical Site Infection Prophylaxis in Adult Orthopaedic Surgery Patients

NCT03401749
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chlorhexidine Gluconate 2% Wipe, Theraworx Bath Wipes
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 64 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Hot Cereal on Digestive Health in Children

NCT02868515
View directory record Official record
Conditions
Subjective Measures of Digestive Health Post Consumption
Interventions
Hot cereal contain 3 g dietary fiber
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
7 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

NCT01269385
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Interventions
alemtuzumab, rituximab, PGG beta-glucan, flow cytometry, laboratory biomarker analysis, DNA analysis, fluorescence in situ hybridization, polymerase chain reaction, polymorphism analysis, mutation analysis
Biological · Drug · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

NCT00002098
View directory record Official record
Conditions
HIV Infections
Interventions
Lentinan, Didanosine
Drug
Lead sponsor
AJI Pharma USA
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California • Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Barley Beta-glucan, Glycemic Control, and Appetite

NCT06146322
View directory record Official record
Conditions
Diet, Healthy, Blood Sugar; High, Diabetes, Appetite and General Nutritional Disorders, Appetitive Behavior
Interventions
WR, LB, MB, HB, WR+50g HFCS, LB + 50 g HFCS, MB + 50 g HFCS, HB + 50 g HFCS
Other
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 20, 2026, 11:57 AM EDT
Recruiting Not applicable Interventional

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

NCT04513028
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
Beta-Glucan
Dietary Supplement
Lead sponsor
Kelly McMasters
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease

NCT02534844
View directory record Official record
Conditions
Niemann-Pick Disease, Type C
Interventions
Parts A/B: Adrabetadex, Parts A/B: Sham Control
Drug · Other
Lead sponsor
Mandos LLC
Industry
Eligibility
4 Years to 21 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 20, 2026, 11:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of a Whole Cell Algae Fermentate on Gut Health and Overall Immune Function in Healthy Adults With Mild Gastrointestinal Issues

NCT04735809
View directory record Official record
Conditions
Healthy, Gastrointestinal Dysfunction, Cold Symptom, Flu Symptom
Interventions
Whole Cell Algae Fermentate, Placebo
Dietary Supplement
Lead sponsor
Kemin Foods LC
Industry
Eligibility
21 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 20, 2026, 11:57 AM EDT
Recruiting Phase 2 Interventional

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

NCT06057948
View directory record Official record
Conditions
Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
Interventions
OPT-821 (QS-21), oral β-glucan
Biological · Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 20, 2026, 11:57 AM EDT